Ongoing phase III trials of semaglutide for Alzheimer’s disease (EVOKE/EVOKE+) will offer further insights into whether newer GLP-1 medicines may protect against Alzheimer’s disease. The gene discussed is GLP1R; the disease is Alzheimer disease.